BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9666865)

  • 1. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
    Greenman Y; Tordjman K; Stern N
    Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprolactinaemia in males: a heterogeneous disorder.
    Walsh JP; Pullan PT
    Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible weight gain and prolactin levels--long-term follow-up in childhood.
    Galluzzi F; Salti R; Stagi S; La Cauza F; Chiarelli F
    J Pediatr Endocrinol Metab; 2005 Sep; 18(9):921-4. PubMed ID: 16279371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for macroprolactinaemia and pituitary imaging studies.
    Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.
    Sawers HA; Robb OJ; Walmsley D; Strachan FM; Shaw J; Bevan JS
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):321-6. PubMed ID: 9156042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy.
    Howlett TA; Wass JA; Grossman A; Plowman PN; Charlesworth M; Touzel R; Rees LH; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1989 Feb; 30(2):131-40. PubMed ID: 2612015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprolactinaemia and pituitary adenomas in adolescence.
    Dissaneevate P; Warne GL
    J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
    Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.
    Zaidi HA; Cote DJ; Castlen JP; Burke WT; Liu YH; Smith TR; Laws ER
    World Neurosurg; 2017 Jan; 97():2-7. PubMed ID: 27671881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breastfeeding a baby with mother on Bromocripine.
    Verma S; Shah D; Faridi MM
    Indian J Pediatr; 2006 May; 73(5):435-6. PubMed ID: 16741332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
    Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
    J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment issues in female hyperprolactinaemia.
    Crosignani PG
    Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication and marked hyperprolactinaemia: iatros or true prolactinoma?
    Koves IH; Jarman FC; Cameron FJ
    Acta Paediatr; 2004 Nov; 93(11):1543-7. PubMed ID: 15513588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speed of response to dopaminergic agents in prolactinomas.
    Hage C; Salvatori R
    Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinaemia.
    Prabhakar VK; Davis JR
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.